Hims & Hers Shares Surge on FDA's Regulatory Shift for Peptides
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy HIMS?
Source: seekingalpha
- Stock Surge: Hims & Hers (HIMS) shares rose as much as 11% in premarket trading on Thursday, poised to extend their approximately 14% rally from Wednesday, indicating strong market optimism regarding the company's future prospects.
- FDA Regulatory Impact: HHS Secretary Robert F. Kennedy Jr. announced that the FDA is seeking to lift restrictions on 12 peptides, a move that could shift market demand away from black market sources and enhance legitimate access to these products.
- Production Licensing Outlook: The FDA plans to convene an advisory committee of independent experts in July to review evidence on certain peptides, and if regulations are eased, Hims & Hers has indicated plans to offer these products, potentially expanding its market share.
- Strategic Company Adjustments: Hims Chief Medical Officer Pat Carroll stated that the FDA's actions will help transition peptide therapies from the gray market to trusted channels, reflecting the company's commitment to consumer safety and clinical excellence.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HIMS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HIMS
Wall Street analysts forecast HIMS stock price to rise
12 Analyst Rating
3 Buy
6 Hold
3 Sell
Hold
Current: 21.360
Low
16.50
Averages
32.95
High
60.00
Current: 21.360
Low
16.50
Averages
32.95
High
60.00
About HIMS
Hims & Hers Health, Inc. provides a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of chronic conditions, including those related to sexual health, hair loss, dermatology, mental health, and weight loss. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies on a subscription basis. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products. Through its mobile applications, consumers can access a range of educational programs, wellness content, and other services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Hims & Hers Health Stock Rises on Peptide Policy Changes
- Policy Impact: Health Secretary Kennedy announced that the FDA will remove 12 peptides from the high-risk category, potentially allowing Hims & Hers Health (HIMS) to expand in the peptide market, leading to a 14% stock price increase.
- Expert Evaluation Meetings: Starting in July, the Pharmacy Compounding Advisory Committee will rigorously assess each peptide's scientific merits and safety, which may shift market demand away from black market products and enhance regulatory access.
- Positive Market Reaction: Retail sentiment around HIMS shifted from 'bearish' to 'bullish', with message volume increasing significantly, indicating strong market interest in peptides and investor hopes for stock prices to rise to $45 or even $100.
- Analyst Rating Discrepancies: Among the 15 analysts covering HIMS, only 3 rated it as 'Buy', while 12 maintained a 'Hold' rating, with a 12-month average price target of $24, reflecting a cautious outlook on the stock's future performance.
See More
Hims & Hers Shares Surge on FDA's Regulatory Shift for Peptides
- Stock Surge: Hims & Hers (HIMS) shares rose as much as 11% in premarket trading on Thursday, poised to extend their approximately 14% rally from Wednesday, indicating strong market optimism regarding the company's future prospects.
- FDA Regulatory Impact: HHS Secretary Robert F. Kennedy Jr. announced that the FDA is seeking to lift restrictions on 12 peptides, a move that could shift market demand away from black market sources and enhance legitimate access to these products.
- Production Licensing Outlook: The FDA plans to convene an advisory committee of independent experts in July to review evidence on certain peptides, and if regulations are eased, Hims & Hers has indicated plans to offer these products, potentially expanding its market share.
- Strategic Company Adjustments: Hims Chief Medical Officer Pat Carroll stated that the FDA's actions will help transition peptide therapies from the gray market to trusted channels, reflecting the company's commitment to consumer safety and clinical excellence.
See More
S&P 500 Index Surpasses 7,000 Mark
- Market Sentiment Rebound: The S&P 500 index surpassed 7,000 on Wednesday, driven by easing Middle East tensions and strong tech performance, with retail investor sentiment shifting from neutral to bullish, indicating a recovery in market confidence.
- Tech Stock Momentum: The Nasdaq index also crossed 26,000 in the previous session, with Nasdaq futures up 0.4% and S&P 500 futures gaining 0.2%, reflecting sustained investor interest and optimism in technology stocks.
- TSMC's Strong Earnings: Taiwan Semiconductor Manufacturing Company reported a record Q1 profit jump of 58%, exceeding estimates, and expects Q2 revenue between $39 billion and $40.2 billion with gross margins of 65.5% to 67.5%, highlighting robust market demand and profitability.
- Economic Data Watch: Investors are closely monitoring upcoming economic data releases, including Initial Jobless Claims and the Philadelphia Fed Manufacturing Index, which could influence market momentum and determine future investment strategies.
See More
FDA Reviews Peptide Substances, HIMS Stock Surges
- FDA Advisory Meetings Scheduled: The FDA has scheduled meetings on July 23-24 to review several peptide substances for potential inclusion on the 503A Bulks List, which could open new revenue opportunities for HIMS amid evolving FDA policies.
- BofA Raises Price Target: Bank of America raised HIMS's price target from $21 to $25, reflecting optimism about potential revenue upside from FDA peptide policy developments, which may enhance the company's market competitiveness.
- Positive Market Reaction: HIMS shares surged over 10% in premarket trading, indicating strong investor optimism regarding the upcoming FDA meetings and potential new revenue streams, showcasing confidence in the company's future growth.
- Shift Towards Branded Treatments: HIMS is transitioning its weight-loss business towards FDA-approved branded GLP-1 therapies, planning to discontinue compounded GLP-1 alternatives, with the CEO stating that shipments of Novo Nordisk medicines have begun, aiming for over 100,000 prescriptions monthly, thus solidifying its market position.
See More
U.S. Stocks Hit Record Highs as Oil Prices Steady
- Strong Market Performance: The S&P 500 and Nasdaq Composite closed at record highs on Wednesday, rising 0.8% and 1.59% respectively, reflecting investor optimism ahead of the upcoming earnings season, which could drive further stock market gains.
- Oil Prices Steady: West Texas Intermediate (WTI) crude prices stabilized around $91 per barrel, while Brent crude hovered near $95, as Washington and Tehran considered extending a ceasefire to facilitate negotiations, alleviating market concerns over energy supply disruptions.
- Investor Sentiment Rebounds: Trump's remarks in an interview that the Iran war is “very close to over” and that Tehran is eager to make a deal bolstered market confidence regarding a potential easing of tensions, contributing to the stock market rally.
- Stock Movements: Hims & Hers Health saw a 14% increase during regular trading after the FDA announced the removal of 12 peptides from the high-risk drug category, highlighting the company's potential in the health sector and attracting investor interest.
See More
FDA Reviews Compounding Pharmacies for Peptide Manufacturing
- Peptide Drug Review: The FDA convened an independent advisory group to discuss allowing compounding pharmacies to manufacture specific peptides, which were removed from the list of drugs permitted for compounding in 2023, indicating a potential shift in regulatory policy that could impact market supply.
- Meeting Schedule: The upcoming meetings will focus on seven peptides scheduled for July 23 and 24, while another five will be reviewed at a future meeting before the end of February 2027, highlighting the FDA's ongoing scrutiny of peptide drugs.
- Growing Market Demand: Peptides are gaining attention for their vital roles in biological functions such as collagen formation and inflammation, particularly due to promotion by online influencers, despite limited data on their effectiveness and safety, which may create market opportunities for related companies.
- Policy Advocacy: Health Secretary Robert F. Kennedy Jr. stated in a podcast that he is advocating for the FDA to reverse restrictions on peptides, emphasizing his personal positive experiences with their use, which could influence public acceptance and demand for peptide products.
See More
Hims & Hers Health Stock Rises on Peptide Policy Changes
- Policy Impact: Health Secretary Kennedy announced that the FDA will remove 12 peptides from the high-risk category, potentially allowing Hims & Hers Health (HIMS) to expand in the peptide market, leading to a 14% stock price increase.
- Expert Evaluation Meetings: Starting in July, the Pharmacy Compounding Advisory Committee will rigorously assess each peptide's scientific merits and safety, which may shift market demand away from black market products and enhance regulatory access.
- Positive Market Reaction: Retail sentiment around HIMS shifted from 'bearish' to 'bullish', with message volume increasing significantly, indicating strong market interest in peptides and investor hopes for stock prices to rise to $45 or even $100.
- Analyst Rating Discrepancies: Among the 15 analysts covering HIMS, only 3 rated it as 'Buy', while 12 maintained a 'Hold' rating, with a 12-month average price target of $24, reflecting a cautious outlook on the stock's future performance.
See More
Hims & Hers Shares Surge on FDA's Regulatory Shift for Peptides
- Stock Surge: Hims & Hers (HIMS) shares rose as much as 11% in premarket trading on Thursday, poised to extend their approximately 14% rally from Wednesday, indicating strong market optimism regarding the company's future prospects.
- FDA Regulatory Impact: HHS Secretary Robert F. Kennedy Jr. announced that the FDA is seeking to lift restrictions on 12 peptides, a move that could shift market demand away from black market sources and enhance legitimate access to these products.
- Production Licensing Outlook: The FDA plans to convene an advisory committee of independent experts in July to review evidence on certain peptides, and if regulations are eased, Hims & Hers has indicated plans to offer these products, potentially expanding its market share.
- Strategic Company Adjustments: Hims Chief Medical Officer Pat Carroll stated that the FDA's actions will help transition peptide therapies from the gray market to trusted channels, reflecting the company's commitment to consumer safety and clinical excellence.
See More
S&P 500 Index Surpasses 7,000 Mark
- Market Sentiment Rebound: The S&P 500 index surpassed 7,000 on Wednesday, driven by easing Middle East tensions and strong tech performance, with retail investor sentiment shifting from neutral to bullish, indicating a recovery in market confidence.
- Tech Stock Momentum: The Nasdaq index also crossed 26,000 in the previous session, with Nasdaq futures up 0.4% and S&P 500 futures gaining 0.2%, reflecting sustained investor interest and optimism in technology stocks.
- TSMC's Strong Earnings: Taiwan Semiconductor Manufacturing Company reported a record Q1 profit jump of 58%, exceeding estimates, and expects Q2 revenue between $39 billion and $40.2 billion with gross margins of 65.5% to 67.5%, highlighting robust market demand and profitability.
- Economic Data Watch: Investors are closely monitoring upcoming economic data releases, including Initial Jobless Claims and the Philadelphia Fed Manufacturing Index, which could influence market momentum and determine future investment strategies.
See More
FDA Reviews Peptide Substances, HIMS Stock Surges
- FDA Advisory Meetings Scheduled: The FDA has scheduled meetings on July 23-24 to review several peptide substances for potential inclusion on the 503A Bulks List, which could open new revenue opportunities for HIMS amid evolving FDA policies.
- BofA Raises Price Target: Bank of America raised HIMS's price target from $21 to $25, reflecting optimism about potential revenue upside from FDA peptide policy developments, which may enhance the company's market competitiveness.
- Positive Market Reaction: HIMS shares surged over 10% in premarket trading, indicating strong investor optimism regarding the upcoming FDA meetings and potential new revenue streams, showcasing confidence in the company's future growth.
- Shift Towards Branded Treatments: HIMS is transitioning its weight-loss business towards FDA-approved branded GLP-1 therapies, planning to discontinue compounded GLP-1 alternatives, with the CEO stating that shipments of Novo Nordisk medicines have begun, aiming for over 100,000 prescriptions monthly, thus solidifying its market position.
See More
U.S. Stocks Hit Record Highs as Oil Prices Steady
- Strong Market Performance: The S&P 500 and Nasdaq Composite closed at record highs on Wednesday, rising 0.8% and 1.59% respectively, reflecting investor optimism ahead of the upcoming earnings season, which could drive further stock market gains.
- Oil Prices Steady: West Texas Intermediate (WTI) crude prices stabilized around $91 per barrel, while Brent crude hovered near $95, as Washington and Tehran considered extending a ceasefire to facilitate negotiations, alleviating market concerns over energy supply disruptions.
- Investor Sentiment Rebounds: Trump's remarks in an interview that the Iran war is “very close to over” and that Tehran is eager to make a deal bolstered market confidence regarding a potential easing of tensions, contributing to the stock market rally.
- Stock Movements: Hims & Hers Health saw a 14% increase during regular trading after the FDA announced the removal of 12 peptides from the high-risk drug category, highlighting the company's potential in the health sector and attracting investor interest.
See More
FDA Reviews Compounding Pharmacies for Peptide Manufacturing
- Peptide Drug Review: The FDA convened an independent advisory group to discuss allowing compounding pharmacies to manufacture specific peptides, which were removed from the list of drugs permitted for compounding in 2023, indicating a potential shift in regulatory policy that could impact market supply.
- Meeting Schedule: The upcoming meetings will focus on seven peptides scheduled for July 23 and 24, while another five will be reviewed at a future meeting before the end of February 2027, highlighting the FDA's ongoing scrutiny of peptide drugs.
- Growing Market Demand: Peptides are gaining attention for their vital roles in biological functions such as collagen formation and inflammation, particularly due to promotion by online influencers, despite limited data on their effectiveness and safety, which may create market opportunities for related companies.
- Policy Advocacy: Health Secretary Robert F. Kennedy Jr. stated in a podcast that he is advocating for the FDA to reverse restrictions on peptides, emphasizing his personal positive experiences with their use, which could influence public acceptance and demand for peptide products.
See More
